Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 9Lymphoma, Mantle-Cell 8Breast Neoplasms 7Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell 5Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Recurrence 4Neuroblastoma 4Myelodysplastic Syndromes 4Mycosis Fungoides 4Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Leukemia 4Congenital Abnormalities 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Glioblastoma 3Burkitt Lymphoma 3

Interventions

fludarabine phosphate 18Cyclophosphamide 16Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 11Busulfan 11Tacrolimus 10Mycophenolic Acid 10ruxolitinib 9fludarabine 7Methotrexate 6Cyclosporine 6Radiotherapy 5Aspirin 5Prednisone 4Melphalan 4Imatinib Mesylate 4Biopsy 4Antilymphocyte Serum 4peginterferon alfa-2a 3givinostat hydrochloride 3givinostat 3Stem Cell Transplantation 3Specimen Handling 3Decitabine 3bomedemstat 2Thiotepa 2Surveys and Questionnaires 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methylprednisolone 2Lenalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Polycythemia Vera × Vorinostat × Clear all
NCT00866762 2011-12-12

A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia

Copenhagen University Hospital at Herlev

Phase 2 Unknown
60 enrolled
Myeloid

Hematologic Diseases, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡